Head-to-head · free
Rhythm Pharmaceuticals, Inc. vs SailPoint
RYTM vs SAIL — return on capital, cash generation, margins and balance sheet side by side.
RYTM
3 / 7
measures where RYTM leads
SAIL
4 / 7
measures where SAIL leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | RYTM · FY2025 | SAIL · FY2026 |
|---|---|---|
| Revenue | $189.8M | $1.1B |
| Net income | (196.5M) | (270.1M) |
| Revenue growth (yearly, multi-year) | 56.5% | — |
| Free cash flow | (116.6M) | $64.6M |
| Free cash flow margin | -61.5% | 6.0% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -251.1% | — |
| Gross margin | 89.7% | 64.5% |
| Operating margin | -101.2% | -28.7% |
| Net debt / EBITDA | 0.28x | 3.70x |
Figures are as reported by each company; latest fiscal year shown.
Where Rhythm Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $953000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where SailPoint's cash went (FY2026)
- Capital spending
- $6.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free